1. Medtech Insight
  2. >>Minute Insights

Minute Insight: Xeltis’ Vascular Access Graft Stays Patent In First-In-Human Trial

 
• By Reed Miller

Xeltis’ aXess graft demonstrated high patency rates and no infections after six months in the first-in-human trial.

Minute Insight
• Source: Informa/Alamy

Xeltis’ aXess hemodialysis access graft demonstrated “extremely promising results” in its first-in-human trial.

The graft is made from Xeltis’ proprietary electrospun supramolecular polymer material that promotes regeneration of the patient’s own tissue as the graft gradually bioabsorbs into the body. The company expects...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

More from Medtech Insight

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 
• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.